Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Opioid prescription patterns in long-term disease-free cancer survivors: a retrospective analysis at a single NCI-designated comprehensive cancer center.
Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study examined opioid dose trajectory patterns in a cohort of disease-free cancer survivors who were at least 1 year out from completion of their cancer treatment at a single NCI-designated comprehensive cancer center. PATIENTS AND
methodsWe conducted a retrospective observational cohort study using electronic health records. Individuals diagnosed and treated for cancer with opioid prescriptions between 2004 and 2024 were identified through a combined review of ICD-10/ICD-9 codes. Inclusion criteria encompassed disease-free cancer patients who were prescribed opioids at least 1 year after completion of cancer treatment. Patients with cancer and sickle cell disease or receiving palliative care were excluded from the analysis. Prescriptions were standardized to average daily morphine milligram equivalent (MME) for a period of 24 months. Participants were classified as high-dose (≥ 50 MME/day) or low-dose (< 50 MME/day) persisters based on the strength of their average daily MMEs 1 year after completion of their cancer treatment. Prescription patterns were elicited using group-based trajectory modeling, and linear mixed-effects regression models.
resultsA total of 1688 disease-free cancer survivors were identified, with 610 being prescribed opioids 1 year after completion of their cancer treatment. Low-dose persisters (n = 404) exhibited two trajectories: discontinuers (61.7%) and escalators (38.3%). Low-dose escalators increased from < 50 MMEs/day to an average of 100 MMEs/day at 24 months. High-dose persisters, i.e., individuals on ≥ 50 MMEs/day (n = 206) at 1 year after completion of their cancer treatment, exhibited escalating doses up to 250 MMEs at 24 months. Sex and race were the only sociodemographic characteristics found to be significant predictors of continued opioid exposure.
conclusionIn our cohort of 610 disease-free cancer survivors on opioids at least 1 year after completion of their cancer treatment, 59.2% (n = 361) were prescribed escalating doses of opioids. Since higher opioid doses have been shown to be associated with increased risks of harm, future multicenter studies are needed to examine the factors associated with increasing opioid doses as well as intervention strategies to mitigate opioid escalation in disease-free cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.